GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its price target trimmed by Cantor Fitzgerald from $211.00 to $193.00 in a research note released on Monday, MarketBeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on the stock. Bank of America reissued a buy rating and set a $197.00 target price (up from $181.00) on shares of GW Pharmaceuticals PLC- in a research note on Friday, September 28th. Morgan Stanley boosted their target price on shares of GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an overweight rating in a research note on Friday, September 28th. BidaskClub raised shares of GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research note on Saturday, September 22nd. ValuEngine raised shares of GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a research note on Thursday, November 1st. Finally, Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $168.00 target price on the stock in a research note on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $185.38.
NASDAQ GWPH opened at $126.25 on Monday. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of -11.96 and a beta of 2.17. GW Pharmaceuticals PLC- has a 1 year low of $105.12 and a 1 year high of $179.65. The company has a current ratio of 6.66, a quick ratio of 6.34 and a debt-to-equity ratio of 0.01.
Large investors have recently made changes to their positions in the business. Belpointe Asset Management LLC bought a new stake in GW Pharmaceuticals PLC- in the third quarter worth $237,000. Morgan Stanley boosted its holdings in GW Pharmaceuticals PLC- by 14.1% in the third quarter. Morgan Stanley now owns 432,144 shares of the biopharmaceutical company’s stock worth $74,649,000 after purchasing an additional 53,368 shares in the last quarter. B. Riley Wealth Management Inc. bought a new stake in GW Pharmaceuticals PLC- in the third quarter worth $656,000. Koshinski Asset Management Inc. bought a new stake in GW Pharmaceuticals PLC- in the third quarter worth $353,000. Finally, Macquarie Group Ltd. bought a new stake in GW Pharmaceuticals PLC- in the third quarter worth $68,339,000. 69.38% of the stock is currently owned by institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Read More: What is insider trading?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.